Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -192.50x is 42% above its 2-year average of -333.45x, near the high end of its 2-year range (-746.79x–-130.53x).
25.25% below its 12-month average of -153.69x.
Reported quarterly interest coverage; no daily interpolation. Q2 FY2026 (2026-06-30): -136.79x.
INTEREST COVERAGE RATIO
-192.50x
INTEREST COVERAGE RATIO AVG TTM
-153.69x
INTEREST COVERAGE RATIO AVG 3Y
-333.45x
INTEREST COVERAGE RATIO AVG 5Y
-333.45x
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-25.25%
CURRENT VS 3Y AVG
+42.27%
CURRENT VS 5Y AVG
+42.27%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-5.63x
median of 444 covered companies
CURRENT VS SECTOR MEDIAN
-3316.15%
vs the sector median at left
Allogene Therapeutics, Inc.
Market Cap
$510.83M
Interest Coverage Ratio
-192.50x
TTM Avg
-153.69x
3Y Avg
-333.45x
5Y Avg
-333.45x
Market Cap
$501.67M
Interest Coverage Ratio
-99.49x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$521.87M
Interest Coverage Ratio
-57.76x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$522.07M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$523.02M
Interest Coverage Ratio
-69.85x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$489.14M
Interest Coverage Ratio
5.63x
TTM Avg
4.06x
3Y Avg
3.16x
5Y Avg
2.54x
Market Cap
$539.42M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $510.83M | -192.50x | -153.69x | -333.45x | -333.45x |
| 908 Devices Inc. (MASS)vs › | $515.72M | N/A | N/A | N/A | N/A |
| Oculis Holding AG (OCS)vs › | $501.67M | -99.49x | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $521.87M | -57.76x | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $522.07M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $523.02M | -69.85x | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $490.95M | -1.91x | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $489.14M | 5.63x | 4.06x | 3.16x | 2.54x |
| Immix Biopharma, Inc. (IMMX)vs › | $539.42M | N/A | N/A | N/A | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $540.09M | -2.35x | N/A | N/A | N/A |
Interest Coverage
-192.5x
Debt/Equity
0.16
Current Ratio
10.72
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-06-30 | -136.79x |
| 2026-03-31 | -153.64x |
| 2025-12-31 | -135.48x |
| 2025-09-30 | -130.53x |
| 2025-06-30 | -212.01x |
| 2025-03-31 | -434.61x |
| 2024-12-31 | -746.79x |
| 2024-09-30 | -717.74x |
| 2018-09-30 | -6.61x |
